Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cimetidine does not alter sparfloxacin pharmacokinetics

J M Gries1, J Honorato, A M Taburet

  • 1Clinical Pharmacy, Hôpital Necker, Paris, France.

International Journal of Clinical Pharmacology and Therapeutics
|November 1, 1995
PubMed
Summary

Cimetidine does not affect the pharmacokinetics of sparfloxacin. This drug interaction study found no significant changes in absorption, metabolism, or excretion, indicating patient safety when using both medications together.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Economic impact of managing invasive mold disease with isavuconazole compared with liposomal amphotericin B followed by posaconazole in Spain.

Expert review of anti-infective therapy·2024
Same author

Recommendations on the use of azole antifungals in hematology-oncology patients.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2023
Same author

Interactions listed in the Paxlovid fact sheet, classified according to risks, pharmacological groups, and consequences.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2022
Same author

Recommendations for antibiotic selection for severe nosocomial infections.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2021
Same author

3D-Printed Franz cells - update on optimization of manufacture and evaluation.

International journal of cosmetic science·2020
Same author

3D-printed Franz type diffusion cells.

International journal of cosmetic science·2018

Area of Science:

  • Pharmacology
  • Drug Interactions
  • Clinical Pharmacology

Background:

  • Cimetidine is a common medication that can inhibit cytochrome P450 enzymes.
  • Sparfloxacin is a fluoroquinolone antibiotic with potential drug interactions.
  • Understanding the interaction between cimetidine and sparfloxacin is crucial for patient safety.

Purpose of the Study:

  • To investigate the pharmacokinetic interaction between cimetidine and sparfloxacin in healthy volunteers.
  • To determine if cimetidine affects the absorption, metabolism, or excretion of sparfloxacin.

Main Methods:

  • A randomized, placebo-controlled study was conducted in 10 healthy volunteers.
  • Participants received a single oral dose of 400 mg sparfloxacin on day 3 of an 8-day treatment period.

Related Experiment Videos

  • Treatments included either cimetidine (400 mg t.i.d.) or a placebo.

    • Main Results:

    • No statistically significant differences were observed in key pharmacokinetic parameters of sparfloxacin, including Cmax, AUC, T1/2, urinary excretion, and metabolic ratio.
    • Cimetidine did not alter the absorption, metabolism, or urinary excretion of sparfloxacin.

    Conclusions:

    • Cimetidine does not significantly impact the pharmacokinetics of sparfloxacin.
    • The combination of cimetidine and sparfloxacin is considered safe, with no increased risk to patients.